跳至主要内容
临床试验/NCT07635693
NCT07635693招募中不适用

ATLG Levels and Immune Reconstitution Kinetics in Autologous HSCT for Multiple Sclerosis

Ciceri Fabio1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年5月4日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Ciceri Fabio
入组人数
20
试验地点
1

研究概览

简要总结

This is a prospective, observational, biological, multicenter study to investigate IR profile, ATLG dynamics, main HSCT and disease outcomes in MS. This study will provide a preliminary descriptive evaluation of key study parameters, including ATLG pharmacokinetics and immune reconstitution trends, as well as an initial assessment of variability (e.g., dispersion of immunological biomarkers), to support the interpretation of results and the design of future studies. Since this is an observational study, no clinical decision will be made, and the interim analysis will not have an impact of the study conduction, and it will not be a stopping rule.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant is willing and able to give informed consent for participation in the study.
  • Adult patients (age >/= 18y)
  • Diagnosis of MS
  • Confirmed program of autologous HSCT according to standard EBMT indications (any conditioning regimen considered standard, BEAM or Cyclophosphamide)
  • ATLG (total dose 30 mg/kg over 3 days: 10 mg/kg on days -3, -2 and -1) in the conditioning regimen.

排除标准

  • Subjects that did not accept to sign the informed consent.
  • Use of ATG.
  • Contraindications to HSCT procedures (including pregnancy and breast feeding, uncontrolled active infections)

研究者

发起方
Ciceri Fabio
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ciceri Fabio

Professor

IRCCS San Raffaele

研究点 (1)

Loading locations...

相似试验